检索

期
标题
作者
卷 95, 编号 9 (2023)
Five-year dynamics adrenergic reactivity of erythrocytes after radio-frequency sympathic denervation of renal arteries in patients with resistant arterial hypertension
Rebrova T., Falkovskaya A., Afanasiev S., Mordovin V., Zyubanova I., Muslimova E.
PDF
(Rus)
卷 95, 编号 4 (2023)
Applying of magnetic resonance tomography for assessment of cardiac remodeling and risk stratification in patients with pulmonary arterial hypertension
Shariya A., Martynyuk T., Shariya M., Ustyuzhanin D.
PDF
(Rus)
卷 95, 编号 9 (2023)
Relationship between the pain severity, use of non-steroidal anti-inflammatory drugs and blood pressure in elective large joint arthroplasty of the lower extremities
Okisheva E., Mironova O., Berdysheva M., Pyatigorets E., Krivova N., Kurnosova A., Elizarov M., Smetanin S., Lychagin A., Fomin V.
PDF
(Rus)
卷 94, 编号 9 (2022)
Ectopic obesity in patients without manifested cardiovascular disease: regulations, frequency and clinical characteristics
Podzolkov V., Bragina A., Osadchiy K., Rodionova Y., Djafarova Z., Khalenyan M., Dishkaya S.
PDF
(Rus)
卷 94, 编号 12 (2022)
Subclinical markers of liver damage in patients with arterial hypertension and obesity
Sadulaeva I., Yushchuk E., Khalikova L., Krikunova O., Trofimenko O., Medvedeva E.
PDF
(Rus)
卷 94, 编号 12 (2022)
Hyperuricemia and kidney damage in patients with cardiovascular disease: A review
Mironova O.
PDF
(Rus)
卷 94, 编号 12 (2022)
Pharmacoepidemiological analysis of antihypertensive therapy in older age groups with senile asthenia syndrome
Davidov E., Yaskevich R.
PDF
(Rus)
卷 93, 编号 12 (2021)
The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders
Nevzorova V., Petrichko T., Chazova I., Zhernakova J.
PDF
(Rus)
卷 94, 编号 3 (2022)
Comments on the article by Professor Dmitry D. Pletnev “Hypertension (the experience of analyzing its genesis)”
Baranova I.
PDF
(Rus)
卷 95, 编号 9 (2023)
Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review
Zakiev V., Kotovskaya Y., Tkacheva O.
PDF
(Rus)
卷 92, 编号 3 (2020)
Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world
Zakiev V., Gvozdeva A., Martynyuk T.
PDF
(Rus)
卷 91, 编号 9 (2019)
Endothelial dysfunction in patients with controlled and uncontrolled arterial hypertension
Podzolkov V., Safronova T., Natkina D.
PDF
(Rus)
卷 91, 编号 2 (2019)
Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases
Maev I., Yurenev G., Mironova E., Yureneva-Thorzhevskaya T.
PDF
(Rus)
卷 85, 编号 12 (2013)
Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
Tsareva N.
卷 90, 编号 9 (2018)
Renal denervation with a resistant arterial hypertension: the results of a five-year follow-up
Glybochko P., Svetankova A., Rodionov A., Maltseva A., Sulimov V., Fomin V.
PDF
(Rus)
卷 92, 编号 12 (2020)
Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia
Shmalts A., Gorbachevsky S.
PDF
(Rus)
卷 90, 编号 4 (2018)
New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
Martynyuk T., Nakonechnikov S., Chazova I.
PDF
(Rus)
卷 93, 编号 9 (2021)
Evidence base for specific pulmonary vasodilators in adults with congenital heart disease
Shmalts A., Gorbachevsky S.
PDF
(Rus)
卷 91, 编号 12 (2019)
A systematic review as a method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults
Shmalts A., Gorbachevsky S.
PDF
(Rus)
卷 90, 编号 3 (2018)
Combination therapy is a new standard for treatment of pulmonary arterial hypertension
Avdeev S., Tsareva N., Gaisin I.
PDF
(Rus)
卷 92, 编号 9 (2020)
The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
Gratsianskaya S., Valieva Z., Martynyuk T.
PDF
(Rus)
卷 92, 编号 12 (2020)
Vascular remodeling with violations of intracardiac hemodynamics in patients older age category, combined with the clinical-cluster, neurocognitive and biomarker heterogeneity in multifocal atherosclerosis
Khasanov A., Bakirov B., Davletshi R., Novikova L., Kudlay D.
PDF
(Rus)
卷 90, 编号 3 (2018)
Pulse wave velocity and other indicators of arterial stiffness in hypertension comorbidity and chronic obstructive pulmonary disease
Aksenova T., Gorbunov V., Tsarenok S.
PDF
(Rus)
卷 93, 编号 1 (2021)
Problems of insufficient control of target blood pressure levels in the outpatient practice
Larina V., Fedorova E., Mikhailusova M., Golovko M.
PDF
(Rus)
卷 92, 编号 9 (2020)
COVID-19 and cardiovascular diseases
Chazova I., Mironova O.
PDF
(Rus)
卷 91, 编号 12 (2019)
Evolution of pathogenetic therapy of pulmonary arterial hypertension
Chazova I., Yarovoy S., Danilov N.
PDF
(Rus)
卷 90, 编号 9 (2018)
Features of the clinical picture in patients of middle age with essential hypertension
Parfenov V., Ostroumova T., Ostroumova O., Pavleyva E.
PDF
(Rus)
卷 91, 编号 1 (2019)
Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry
Chazova I., Arkhipova O., Martynyuk T.
PDF
(Rus)
卷 81, 编号 4 (2009)
Quantitative repolarization indices in diagnosis of left ventricular hypertrophy in hypertensive patients
Sakhnova T., Blinova E., Sergakova L., Ataullakhanova D., Chazova I., Sakhnova T., Blinova E., Sergakova L., Ataullakhanova D., Chazova I.
卷 93, 编号 10 (2021)
Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
Demidova T., Lobanova K., Perekhodov S., Antsiferov M., Oynotkinova O.
PDF
(Rus)
卷 92, 编号 8 (2020)
Association of nutritional patterns and arterial hypertension in Russia: does it exist?
Lantseva M., Sasunova A., Vlasova A., Kropochev V., Pilipenko V., Morozov S., Isakov V.
PDF
(Rus)
卷 91, 编号 9 (2019)
Risk stratification methods and their significance in pulmonary arterial hypertension
Avdeev S., Tsareva N.
PDF
(Rus)
卷 90, 编号 10 (2018)
Prevalence and risk factors of sleep breathing disorders in patients with acromegaly from Moscow region
Kovaleva Y., Dreval A., Kulakov N., Fedorova S., Ilovayskaya I.
PDF
(Rus)
卷 89, 编号 9 (2017)
A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
Tsareva N., Avdeev S., Neklyudova G.
PDF
(Rus)
卷 87, 编号 9 (2015)
Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
Avdeev S.
卷 85, 编号 3 (2013)
First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
Avdeev S., Tsareva N., Nekliudova G., Chuchalin A.
卷 93, 编号 9 (2021)
New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
Dragomiretskaya N., Tarzimanova A., Kucherova J., Podzolkov V.
PDF
(Rus)
卷 93, 编号 6 (2021)
The state of cytokine regulation and endothelial dysfunction in the combined course of vibration disease and arterial hypertension
Babanov S., Baraeva R., Strizhakov L., Moiseev S., Fomin V.
PDF
(Rus)
卷 90, 编号 12 (2018)
The effectiveness of combination antihypertensive therapy in patients with arterial hypertension and additional risk factors: obesity and obstructive sleep apnea syndrome
Elfimova E., Litvin A., Chazova I.
PDF
(Rus) PDF
(Rus)
卷 89, 编号 8 (2017)
Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
Valieva Z., Martynyuk T., Chazova I.
PDF
(Rus)
卷 80, 编号 6 (2008)
Resistent arterial hypertension
Chazova I., Fomin V.
卷 93, 编号 9 (2021)
Tactics of antihypertensive therapy during COVID-19 pandemic
Podzolkov V., Bragina A., Rodionova Y., Bragina G., Bykova E.
PDF
(Rus)
卷 93, 编号 4 (2021)
From palpation of the pulse to cuff-free methods: evolution of arterial pressure measurement methods
Solnceva T., Sivakova O., Chazova I.
PDF
(Rus)
卷 92, 编号 12 (2020)
Association of rs3025058 polymorphism with the development of stroke in patients with cardiovascular pathology
Nikulina S., Shulman V., Chernova A., Prokopenko S., Nikulin D., Platunova I., Tretyakova S., Semenchukov A., Marilovtseva O., Lebedeva I., Maksimov V., Gurazheva A.
PDF
(Rus)
卷 90, 编号 9 (2018)
Vitamin D deficiency and cardiovascular pathology
Podzolkov V., Pokrovskaya A., Panasenko O.
PDF
(Rus)
卷 90, 编号 4 (2018)
Modern view on the place of riociguat in the treatment of pulmonary hypertension
Valieva Z., Taran I., Martynyuk T., Chazova I.
PDF
(Rus)
卷 88, 编号 8 (2016)
Non-drug rehabilitation of patients with chronic obstructive pulmonary disease concurrent with hypertension
Sevostyanova E., Nikolaev Y., Bogdankevich N., Lusheva V., Markova E., Dolgova N.
PDF
(Rus)
卷 80, 编号 6 (2008)
Bilateral stenosis of renal arteries in a patient with primary antiphospholipid syndrome following hemolyticouremic syndrome (a case report and review of literature)
Kozlovskaia N., Bobrova L., Zakharova E., Khafizova E., Gagarina N., Miroshnichenko N.
卷 93, 编号 4 (2021)
Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis
Konradi A., Zvartau N., Chazova I., Zhernakova J., Schutte A., Schlaich M.
PDF
(Rus)
卷 92, 编号 12 (2020)
Detection of kidney dysfunction potential biomarkers with hypertension in the persons of 25–45 years
Kovalkova N., Khudyakova A., Kashtanova E., Polonskaya Y., Shcherbakova L., Ragino Y.
PDF
(Rus)
1 - 50 的 71 信息 1 2 > >> 

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##